Stock Scorecard



Stock Summary for Intellia Therapeutics Inc (NTLA) - $8.07 as of 3/28/2025 8:34:06 PM EST

Total Score

10 out of 30

Safety Score

44 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for NTLA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for NTLA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for NTLA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for NTLA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for NTLA (44 out of 100)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 6
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for NTLA

Promising Genomics & Synthetic Biology Stocks to Consider in 2025 3/28/2025 1:39:00 PM
Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion. - Intellia Therapeutics ( NASDAQ:NTLA ) 3/27/2025 11:48:00 PM
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. ( NTLA ) of a Class Action Lawsuit and an Upcoming Deadline - Intellia Therapeutics ( NASDAQ:NTLA ) 3/27/2025 4:48:00 PM
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication 3/27/2025 3:36:00 PM
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Intellia Therapeutics ( NASDAQ:NTLA ) 3/26/2025 8:00:00 PM
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy ( RMAT ) Designation Granted to Nexiguran Ziclumeran ( nex-z ) for the Treatment of Transthyretin ( ATTR ) Amyloidosis with Cardiomyopathy 3/26/2025 11:30:00 AM
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edison, Elastic, Intellia, and ICON and Encourages Investors to Contact the Firm - Edison Intl ( NYSE:EIX ) , Elastic ( NYSE:ESTC ) 3/26/2025 1:00:00 AM
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - Intellia Therapeutics ( NASDAQ:NTLA ) 3/23/2025 12:54:00 PM
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought 3/21/2025 3:25:00 PM
Cathie Wood Bets On Elon Musk's Tesla Despite Cybertruck Recall, Dumps Zuckerberg's Meta Shares Again - Meta Platforms ( NASDAQ:META ) , ARK Innovation ETF ( ARCA:ARKK ) 3/21/2025 1:29:00 AM

Financial Details for NTLA

Company Overview

Ticker NTLA
Company Name Intellia Therapeutics Inc
Country USA
Description Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Most Recent Quarter 12/31/2024
Next Earnings Date 5/7/2025

Stock Price History

Last Day Price 8.07
Price 4 Years Ago 118.24
Last Day Price Updated 3/28/2025 8:34:06 PM EST
Last Day Volume 2,757,629
Average Daily Volume 3,591,766
52-Week High 28.18
52-Week Low 8.11
Last Price to 52 Week Low 0.49%

Valuation Measures

Trailing PE N/A
Industry PE 28.22
Sector PE 40.10
5-Year Average PE -13.52
Free Cash Flow Ratio 1.27
Industry Free Cash Flow Ratio 41.28
Sector Free Cash Flow Ratio 47.05
Current Ratio Most Recent Quarter 6.73
Total Cash Per Share 6.36
Book Value Per Share Most Recent Quarter 8.55
Price to Book Ratio 0.99
Industry Price to Book Ratio 9.46
Sector Price to Book Ratio 21.92
Price to Sales Ratio Twelve Trailing Months 14.86
Industry Price to Sales Ratio Twelve Trailing Months 6.78
Sector Price to Sales Ratio Twelve Trailing Months 27.78
Analyst Buy Ratings 17
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 103,517,000
Market Capitalization 835,382,190
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -1.48%
Reported EPS 12 Trailing Months -5.25
Reported EPS Past Year -5.25
Reported EPS Prior Year -5.41
Net Income Twelve Trailing Months -522,284,000
Net Income Past Year -481,192,000
Net Income Prior Year -474,186,000
Quarterly Revenue Growth YOY -24.00%
5-Year Revenue Growth 7.82%
Operating Margin Twelve Trailing Months -1,060.00%

Balance Sheet

Total Cash Most Recent Quarter 658,114,000
Total Cash Past Year 912,223,000
Total Cash Prior Year 1,192,622,000
Net Cash Position Most Recent Quarter 658,114,000
Net Cash Position Past Year 912,223,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 1,050,169,000
Total Stockholder Equity Prior Year 1,235,584,000
Total Stockholder Equity Most Recent Quarter 962,615,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -363,056,000
Free Cash Flow Per Share Twelve Trailing Months -3.51
Free Cash Flow Past Year -408,071,000
Free Cash Flow Prior Year -346,845,000

Options

Put/Call Ratio 0.14
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.51
MACD Signal -0.44
20-Day Bollinger Lower Band 7.35
20-Day Bollinger Middle Band 11.41
20-Day Bollinger Upper Band 15.47
Beta 1.97
RSI 38.74
50-Day SMA 18.17
150-Day SMA 33.22
200-Day SMA 52.60

System

Modified 3/28/2025 3:21:02 AM EST